Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Heart Transplant Rejection Overview 5 Therapeutics Development 6 Pipeline Products for Heart Transplant Rejection - Overview 6 Pipeline Products for Heart Transplant Rejection - Comparative Analysis 7 Heart Transplant Rejection - Therapeutics under Development by Companies 8 Heart Transplant Rejection - Pipeline Products Glance 9 Early Stage Products 9 Heart Transplant Rejection - Products under Development by Companies 10 Heart Transplant Rejection - Companies Involved in Therapeutics Development 11 Astellas Pharma Inc 11 Nekonal Sarl 12 Noxxon Pharma AG 13 Pelican Therapeutics Inc 14 Heart Transplant Rejection - Therapeutics Assessment 15 Assessment by Monotherapy Products 15 Assessment by Target 16 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 23 AS-2521780 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 emapticap pegol - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 PTX-15 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Heart Transplant Rejection - Dormant Projects 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 30 Disclaimer 31

List of Tables Number of Products under Development for Heart Transplant Rejection, H2 2016 6 Number of Products under Development for Heart Transplant Rejection - Comparative Analysis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Early Stage Development, H2 2016 9 Products under Development by Companies, H2 2016 10 Heart Transplant Rejection - Pipeline by Astellas Pharma Inc, H2 2016 11 Heart Transplant Rejection - Pipeline by Nekonal Sarl, H2 2016 12 Heart Transplant Rejection - Pipeline by Noxxon Pharma AG, H2 2016 13 Heart Transplant Rejection - Pipeline by Pelican Therapeutics Inc, H2 2016 14 Assessment by Monotherapy Products, H2 2016 15 Number of Products by Stage and Target, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 19 Number of Products by Stage and Route of Administration, H2 2016 21 Number of Products by Stage and Molecule Type, H2 2016 22 Heart Transplant Rejection - Dormant Projects, H2 2016 29 List of Figures Number of Products by Top 10 Targets, H2 2016 16 Number of Products by Stage and Top 10 Targets, H2 2016 16 Number of Products by Top 10 Mechanism of Actions, H2 2016 18 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 18 Number of Products by Routes of Administration, H2 2016 20 Number of Products by Stage and Routes of Administration, H2 2016 20 Number of Products by Molecule Types, H2 2016 22

Astellas Pharma Inc Nekonal Sarl Noxxon Pharma AG Pelican Therapeutics Inc